Propylparaben
Also known as Propyl parahydroxybenzoate, Propyl p-hydroxybenzoate, Nipasol, Propylparaben
“CIR Expert Panel says: safe as used in cosmetics.”
Propylparaben (propyl p-hydroxybenzoate; CAS 94-13-3; C10H12O3) is a mid-chain paraben ester with extensive regulatory review history. CIR's 2008 group re-review (IJT 27(S4):1-82, PMID 19101832) concluded propylparaben safe as used in cosmetics (unconditional 'S' in QRT). The 2013 SCCS revised opinion (SCCS/1514/13) found propylparaben safe at up to 0.4% (as acid) for general consumer use but imposed a pediatric restriction: not to be used in products intended for the nappy/diaper area in children under 3 years — a restriction that does not apply to methylparaben or ethylparaben. A 2021 SCCS Final Opinion specifically on propylparaben (SCCS/1623/20, PMID 34274358) further tightened the limit to 0.14% (as acid), noting some indications of potential endocrine effects while concluding insufficient data to classify it as an endocrine disruptor. Both CIR and SCCS explicitly addressed estrogenicity; SCCS's progressive tightening from 0.4% (2013) to 0.14% (2021) reflects precautionary action on the endocrine signal rather than a finding of harm at cosmetic-use concentrations.
One of the most extensively studied cosmetic preservatives globally; long CIR and SCCS review history with detailed toxicological dataset
Broad-spectrum antimicrobial activity; effective against bacteria, molds, and yeasts; often used in combination with methylparaben for synergistic coverage
Oil-soluble; compatible with a wide pH range; useful in both emulsion phases and anhydrous systems
CIR unconditional 'S' finding (2008) and SCCS approved status (with concentration and pediatric restrictions) make regulatory status for adult products in general use clear
Endocrine disruption concern: propylparaben has measurably higher estrogenic potency than short-chain parabens (methyl, ethyl); Boberg et al. 2010 flagged that safety margins may be inadequate under worst-case exposure scenarios; SCCS/1623/20 (2021) acknowledged indications of potential endocrine effects but stopped short of classifying propylparaben as an endocrine disruptor
SCCS/1514/13 pediatric restriction: propylparaben is prohibited in leave-on products applied to the nappy/diaper area of children under 3 years due to precautionary concern about endocrine sensitivity in infants; this restriction does not apply to methylparaben or ethylparaben
Progressive regulatory tightening: SCCS reduced the permitted concentration from 0.4% (2013) to 0.14% (2021), signaling ongoing regulatory concern about cumulative paraben exposure and endocrine effects; formulators should use the 0.14% limit as the operative cap
Paraben detection in breast tissue: Darbre et al. 2004 reported paraben detection in breast tumor tissue; this finding has been widely discussed in consumer and advocacy contexts; regulatory bodies evaluated it and did not find it sufficient to establish causation or warrant banning propylparaben, but it contributes to ongoing consumer wariness
CIR Quick Reference Table (12/2017, revised 07/2018) — PROPYLPARABEN row: Finding=S, Citation=IJT 27(S4):1-82, 2008; JACT 3(5):147-209, 1…
“Propylparaben S IJT 27(S4): 1-82, 2008 JACT 3(5):147-209, 1984 (original report)”— QRT-122017revised072018.pdf, p. 113
SCCS/1514/13 — Revised Opinion on Parabens (10 December 2013): propylparaben-specific sections restricting use in nappy/diaper-area produ…
SCCS/1623/20 — Final Opinion on Propylparaben (CAS 94-13-3), published Regul Toxicol Pharmacol 2021 (PMID 34274358): safe as preservative…
“propylparaben is safe when used as a preservative in cosmetic products up to a maximum concentration of 0.14%”— PMID 34274358 (SCCS/1623/20) abstract / conclusions